Archer Aviation vs. Kraken Robotics: With Geopolitical Risk Rising, Which Defense Stock Wins?

Kraken Robotics is positioned as the preferred defense stock over Archer Aviation, with 2025 sales of about CA$102 million, 62.1% gross margin last year, and guidance for 55%-60% gross margin this year. Archer remains earlier stage, with just $1.6 million of Q1 revenue, a $618.2 million net loss last year, and a longer path to profitability. The article also highlights Kraken’s planned Covelya acquisition and Anduril-related defense partnerships as additional growth catalysts.

Analysis

The market is likely underestimating how much of the defense value proposition here is really a manufacturing and integration story, not a pure end-market story. Kraken’s advantage is that it is already monetizing programs with real deployment cadence, so incremental defense demand should flow faster into revenue and margin than Archer’s more binary certification path. In other words, Kraken looks like the cleaner “picks-and-shovels” way to express autonomous defense spending, while Archer remains a longer-duration option on regulatory execution and urban-air mobility adoption.

The second-order effect is that Kraken’s acquisition-led expansion could create a more defensible moat if it converts into bundled maritime systems and higher switching costs. That should also improve cross-selling into the same prime-contractor ecosystem that Anduril is building, which matters because the budget winners in next-gen defense tend to be the vendors that become embedded in platform architectures early. The risk, however, is that M&A integration often masks working-capital drag and hidden margin dilution for 2-4 quarters before synergies show up.

Archer is more vulnerable to timeline slippage than the headline valuation suggests. Any delay in certification or first commercial flights likely compresses multiple expansion because the market is implicitly paying for a near-term transition from narrative to revenue, and that transition is still contingent. If commercialization slips by even one cycle, the stock can de-rate sharply because the equity is being used as a financing instrument as much as a growth asset.

The contrarian angle is that Kraken’s relative outperformance may already be partially priced in, while Archer may be too discounted for a successful “one good news cycle” setup. If Archer clears a visible regulatory milestone, the stock could outperform violently over a short window, but that is a catalyst trade, not a fundamental compounder trade. For longer horizons, Kraken has the better asymmetry because it has less execution binary and a clearer path to operating leverage.

Key Decisions for Investors

• Go long KRKNF on any 3-5% pullback over the next 1-2 weeks; target a 15-20% move over 3-6 months if acquisition synergies and defense order flow translate into sustained margin stability.
• Use ACHR as a catalyst trade only: initiate a small long or call spread into certification/flight milestones over 1-3 months, but cap downside with defined-risk structures because a delay could cut the stock 20%+.
• Pair trade: long KRKNF / short ACHR for a 3-6 month relative-value view; thesis is faster monetization and lower execution risk at Kraken versus binary regulatory risk at Archer.
• If you want optionality on Archer, buy out-of-the-money calls rather than common equity; the payoff is convex if U.S./UAE approvals accelerate, and premium outlay limits damage if timelines slip.
• Trim Kraken only if the market begins pricing the Covelya deal as pure multiple expansion without showing operating leverage; that would signal the trade has moved from fundamentals to story and risk/reward deteriorates.